NasdaqGM:MNKDBiotechs
MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price
Key Insights MannKind's estimated fair value is US$8.9 based on 2 Stage Free Cash Flow to Equity Current share price of...
NasdaqGS:HOWLBiotechs
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
NasdaqCM:MDXGBiotechs
More money in the bank for insiders who divested US$1.7m worth of MiMedx Group, Inc. (NASDAQ:MDXG) shares last year
Despite the fact that MiMedx Group, Inc. (NASDAQ:MDXG) stock rose 12% last week, insiders who sold US$1.7m worth of...
NasdaqGM:ARDXBiotechs
Bullish Ardelyx, Inc. (NASDAQ:ARDX) insiders were rewarded last week as their US$1.0m investment inflated to US$1.9m
Ardelyx, Inc. ( NASDAQ:ARDX ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...
NasdaqGS:SGENBiotechs
Seagen Inc.'s (NASDAQ:SGEN) large institutional owners must be happy as stock continues to impress, up 4.6% over the past week
Key Insights Significantly high institutional ownership implies Seagen's stock prices are sensitive to their trading...
NasdaqGS:BNTXBiotechs
With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
NasdaqGS:RXDXBiotechs
Prometheus Biosciences' Investors Sitting On Solid 262% Return Over Year
Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...
NasdaqGS:XLOBiotechs
Institutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the most
If you want to know who really controls Xilio Therapeutics, Inc. ( NASDAQ:XLO ), then you'll have to look at the makeup...
NasdaqGM:INABBiotechs
Is IN8bio (NASDAQ:INAB) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
NasdaqGS:ABSIBiotechs
Following 27% Rise Last Week, Absci Shareholders Still Down 49% Over Past Year
Absci Corporation ( NASDAQ:ABSI ) shareholders will doubtless be very grateful to see the share price up 50% in the...
NasdaqGS:MGNXBiotechs
Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
NasdaqGM:GRNABiotechs
Private equity firms are GreenLight Biosciences Holdings' (NASDAQ:GRNA) biggest owners and were hit after market cap dropped US$21m
Key Insights Significant control over GreenLight Biosciences Holdings by vc/pe firms implies that this group likely has...
NasdaqCM:IKTBiotechs
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
NasdaqCM:CPRXBiotechs
Is The Market Wrong About Catalyst Pharmaceuticals?
With its stock down 21% over the past week, it is easy to disregard Catalyst Pharmaceuticals (NASDAQ:CPRX). However, a...
NasdaqCM:EPIXBiotechs
Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)
Key Insights ESSA Pharma's estimated fair value is US$3.4 based on 2 Stage Free Cash Flow to Equity Current share price...
NasdaqGS:ORICBiotechs
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
NasdaqGS:ARWRBiotechs
A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Key Insights Arrowhead Pharmaceuticals' estimated fair value is US$31.2 based on 2 Stage Free Cash Flow to Equity...
NasdaqGS:MRNABiotechs
Moderna Rallies 3.3% This Week, Taking Three-Year Gains To 781%
For us, stock picking is in large part the hunt for the truly magnificent stocks. But when you hold the right stock for...
NasdaqGM:PRMEBiotechs
Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
NasdaqCM:BWVBiotechs
Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
NasdaqCM:AZYOBiotechs
Despite recent gains, Aziyo Biologics, Inc. (NASDAQ:AZYO) insiders are still down US$3.0k after purchasing last year
Insiders who bought US$146k worth of Aziyo Biologics, Inc. ( NASDAQ:AZYO ) stock in the last year recovered part of...
NasdaqCM:VKTXBiotechs
Despite Viking Therapeutics, Inc.'s recent decline, insiders have made a around US$269k profit after buying earlier this year.
Viking Therapeutics, Inc. ( NASDAQ:VKTX ) insiders who acquired shares over the previous 12 months, can probably afford...
NasdaqGS:BCRXBiotechs
When Will BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Become Profitable?
BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) is possibly approaching a major achievement in its business, so we would...
NasdaqGS:RXRXBiotechs
Insiders Relieved After Selling Recursion Pharmaceuticals With 5.1% Price Dip
By selling US$164k worth of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) stock at an average sell price of US$8.77...